Impact of Statin or Fibrate Therapy on Homocysteine Concentrations: A Systematic Review and Meta-analysis
- Authors: Akbari A.1, Islampanah M.1, Arhaminiya H.1, Alvandi Fard M.M.1, Jamialahmadi T.2, Sahebkar A.2
-
Affiliations:
- Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences
- Applied Biomedical Research Center, Mashhad University of Medical Sciences
- Issue: Vol 31, No 14 (2024)
- Pages: 1920-1940
- Section: Anti-Infectives and Infectious Diseases
- URL: https://hum-ecol.ru/0929-8673/article/view/644369
- DOI: https://doi.org/10.2174/0929867330666230413090416
- ID: 644369
Cite item
Full Text
Abstract
Introduction:Statins and fibrates are two lipid-lowering drugs used in patients with dyslipidemia. This systematic review and meta-analysis were conducted to determine the magnitude of the effect of statin and fibrate therapy on serum homocysteine levels.
Methods:A search was undertaken of the PubMed, Scopus, Web of Science, Embase, and Google Scholar electronic databases up to 15 July 2022. Primary endpoints focused on plasma homocysteine levels. Data were quantitatively analyzed using fixed or random- effect models, as appropriate. Subgroup analyses were conducted based on the drugs and hydrophilic-lipophilic balance of statins.
Results:After screening 1134 papers, 52 studies with a total of 20651 participants were included in the meta-analysis. The analysis showed a significant decrease in plasma homocysteine levels after statin therapy (WMD: -1.388 µmol/L, 95% CI: [-2.184, -0.592], p = 0.001; I2 = 95%). However, fibrate therapy significantly increased plasma homocysteine levels (WMD: 3.459 µmol/L, 95% CI: [2.849, 4.069], p < 0.001; I2 = 98%). The effect of atorvastatin and simvastatin depended on the dose and duration of treatment (atorvastatin [coefficient: 0.075 [0.0132, 0.137]; p = 0.017, coefficient: 0.103 [0.004, 0.202]; p = 0.040, respectively] and simvastatin [coefficient: -0.047 [-0.063, -0.031]; p < 0.001, coefficient: 0.046 [0.016, 0.078]; p = 0.004]), whereas the effect of fenofibrate persisted over time (coefficient: 0.007 [-0.011, 0.026]; p = 0.442) and was not altered by a change in dosage (coefficient: -0.004 [-0.031, 0.024]; p = 0.798). In addition, the greater homocysteine- lowering effect of statins was associated with higher baseline plasma homocysteine concentrations (coefficient: -0.224 [-0.340, -0.109]; p < 0.001).
Conclusion:Fibrates significantly increased homocysteine levels, whereas statins significantly decreased them.
Keywords
About the authors
Abolfazl Akbari
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences
Email: info@benthamscience.net
Muhammad Islampanah
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences
Email: info@benthamscience.net
Hadise Arhaminiya
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences
Email: info@benthamscience.net
Mohammad Mahdi Alvandi Fard
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences
Email: info@benthamscience.net
Tannaz Jamialahmadi
Applied Biomedical Research Center, Mashhad University of Medical Sciences
Email: info@benthamscience.net
Amirhossein Sahebkar
Applied Biomedical Research Center, Mashhad University of Medical Sciences
Author for correspondence.
Email: info@benthamscience.net
References
- Mangge, H.; Becker, K.; Fuchs, D.; Gostner, J.M. Antioxidants, inflammation and cardiovascular disease. World J. Cardiol., 2014, 6(6), 462-477. doi: 10.4330/wjc.v6.i6.462 PMID: 24976919
- Chen, P.J.; Lu, Y.C.; Wang, P.M.; Huang, C.F.; Loke, S.S. Factors associated with hyperhomocysteinemia in relatively healthy Taiwanese adults. Medicine, 2021, 100(3), e23829. doi: 10.1097/MD.0000000000023829 PMID: 33545948
- Liu, R.; Xu, F.; Zhou, Y.; Liu, T. The characteristics of risk factors in Chinese young women with acute coronary syndrome. BMC Cardiovasc. Disord., 2020, 20(1), 290. doi: 10.1186/s12872-020-01577-z PMID: 32532208
- Akbari, A.; Rafiee, M.; Sathyapalan, T.; Sahebkar, A. Impacts of sodium/glucose cotransporter-2 inhibitors on circulating uric acid concentrations: A systematic review and meta-analysis. J. Diabetes Res., 2022, 2022, 1-17. doi: 10.1155/2022/7520632 PMID: 35224108
- Venes, D. Tabers cyclopedic medical dictionary; FA Davis, 2017.
- Faeh, D.; Chiolero, A.; Paccaud, F. Homocysteine as a risk factor for cardiovascular disease: Should we (still) worry about? Swiss Med. Wkly., 2006, 136(47-48), 745-756. PMID: 17225194
- Ganguly, P.; Alam, S.F. Role of homocysteine in the development of cardiovascular disease. Nutr. J., 2015, 14(1), 6. doi: 10.1186/1475-2891-14-6 PMID: 25577237
- Zhao, J.; Chen, H.; Liu, N.; Chen, J.; Gu, Y.; Chen, J.; Yang, K. Role of hyperhomocysteinemia and hyperuricemia in pathogenesis of atherosclerosis. J. Stroke Cerebrovasc. Dis., 2017, 26(12), 2695-2699. doi: 10.1016/j.jstrokecerebrovasdis.2016.10.012 PMID: 28986198
- Gatt, A.; Makris, M. Hyperhomocysteinemia and venous thrombosis. Semin. Hematol., 2007, 44(2), 70-76. doi: 10.1053/j.seminhematol.2007.01.002 PMID: 17433898
- Durand, P.; Prost, M.; Loreau, N.; Lussier-Cacan, S.; Blache, D. Impaired homocysteine metabolism and atherothrombotic disease. Lab. Invest., 2001, 81(5), 645-672. doi: 10.1038/labinvest.3780275 PMID: 11351038
- Selhub, J.; Jacques, P.F.; Rosenberg, I.H.; Rogers, G.; Bowman, B.A.; Gunter, E.W.; Wright, J.D.; Johnson, C.L. Serum total homocysteine concentrations in the third national health and nutrition examination survey (1991-1994): Population reference ranges and contribution of vitamin status to high serum concentrations. Ann. Intern. Med., 1999, 131(5), 331-339. doi: 10.7326/0003-4819-131-5-199909070-00003 PMID: 10475885
- Kim, J.; Kim, H.; Roh, H.; Kwon, Y. Causes of hyperhomocysteinemia and its pathological significance. Arch. Pharm. Res., 2018, 41(4), 372-383. doi: 10.1007/s12272-018-1016-4 PMID: 29552692
- Sahebkar, A.; Pirro, M.; Reiner, .; Cicero, A.; Ferretti, G.; Simental-Mendía, M.; Simental-Mendía, L. A systematic review and meta-analysis of controlled trials on the effects of statin and fibrate therapies on plasma homocysteine levels. Curr. Med. Chem., 2016, 23(39), 4490-4503. doi: 10.2174/0929867323666161007155310 PMID: 27748179
- Zinellu, A.; Mangoni, A.A. Effect of statin treatment on homocysteine concentrations: An updated systematic review and meta-analysis with meta-regression. Expert Rev. Clin. Pharmacol., 2022, 15(4), 443-459. doi: 10.1080/17512433.2022.2072293 PMID: 35482022
- Bahrami, A.; Bo, S.; Jamialahmadi, T.; Sahebkar, A. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms. Ageing Res. Rev., 2020, 58, 101024. doi: 10.1016/j.arr.2020.101024 PMID: 32006687
- Bland, A.R.; Payne, F.M.; Ashton, J.C.; Jamialahmadi, T.; Sahebkar, A. The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacol. Res., 2022, 175, 105986. doi: 10.1016/j.phrs.2021.105986 PMID: 34800627
- Gorabi, A.M.; Kiaie, N.; Bianconi, V.; Pirro, M.; Jamialahmadi, T.; Sahebkar, A. Statins attenuate fibrotic manifestations of cardiac tissue damage. Curr. Mol. Pharmacol., 2021, 14(5), 782-797. doi: 10.2174/1874467214666210210123206 PMID: 33568040
- Sohrevardi, S.; Nasab, F.; Mirjalili, M.; Bagherniya, M.; Tafti, A.; Jarrahzadeh, M.; Azarpazhooh, M.; Saeidmanesh, M.; Banach, M.; Jamialahmadi, T.; Sahebkar, A. Effect of atorvastatin on delirium status of patients in the intensive care unit: A randomized controlled trial. Arch. Med. Sci., 2019, 17(5), 1423-1428. doi: 10.5114/aoms.2019.89330 PMID: 34522273
- Vahedian-Azimi, A.; Mohammadi, S.; Beni, F.; Banach, M.; Guest, P.; Jamialahmadi, T.; Sahebkar, A. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis. Arch. Med. Sci., 2021, 17(3), 579-595. doi: 10.5114/aoms/132950 PMID: 34025827
- Botta, M.; Audano, M.; Sahebkar, A.; Sirtori, C.; Mitro, N.; Ruscica, M. PPAR agonists and metabolic syndrome: An established role? Int. J. Mol. Sci., 2018, 19(4), 1197. doi: 10.3390/ijms19041197 PMID: 29662003
- Derosa, G.; Sahebkar, A.; Maffioli, P. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. J. Cell. Physiol., 2018, 233(1), 153-161. doi: 10.1002/jcp.25804 PMID: 28098353
- Sahebkar, A.; Chew, G.T.; Watts, G.F. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog. Lipid Res., 2014, 56(1), 47-66. doi: 10.1016/j.plipres.2014.07.002 PMID: 25083925
- Banach, M.; Serban, C.; Ursoniu, S.; Rysz, J.; Muntner, P.; Toth, P.P.; Jones, S.R.; Rizzo, M.; Glasser, S.P.; Watts, G.F.; Blumenthal, R.S.; Lip, G.Y.H.; Mikhailidis, D.P.; Sahebkar, A. Statin therapy and plasma coenzyme Q10 concentrations-A systematic review and meta-analysis of placebo- controlled trials. Pharmacol. Res., 2015, 99, 329-336. doi: 10.1016/j.phrs.2015.07.008 PMID: 26192349
- Bytyçi, I.; Penson, P.E.; Mikhailidis, D.P.; Wong, N.D.; Hernandez, A.V.; Sahebkar, A.; Thompson, P.D.; Mazidi, M.; Rysz, J.; Pella, D.; Reiner, .; Toth, P.P.; Banach, M. Prevalence of statin intolerance: A meta-analysis. Eur. Heart J., 2022, 43(34), 3213-3223. doi: 10.1093/eurheartj/ehac015 PMID: 35169843
- Sahebkar, A.; Cicero, A.F.G.; Di Giosia, P.; Pomilio, I.; Stamerra, C.A.; Giorgini, P.; Ferri, C.; Haehling, S.; Banach, M.; Jamialahmadi, T. Pathophysiological mechanisms of statin-associated myopathies: Possible role of the ubiquitin-proteasome system. J. Cachexia Sarcopenia Muscle, 2020, 11(5), 1177-1186. doi: 10.1002/jcsm.12579 PMID: 32743965
- Scott, R.; OBrien, R.; Fulcher, G.; Pardy, C.; dEmden, M.; Tse, D.; Taskinen, M.R.; Ehnholm, C.; Keech, A. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care, 2009, 32(3), 493-498. doi: 10.2337/dc08-1543 PMID: 18984774
- Yebyo, H.G.; Aschmann, H.E.; Kaufmann, M.; Puhan, M.A. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am. Heart J., 2019, 210, 18-28. doi: 10.1016/j.ahj.2018.12.007 PMID: 30716508
- Sahebkar, A.; Chew, G.T.; Watts, G.F. New peroxisome proliferator-activated receptor agonists: Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin. Pharmacother., 2014, 15(4), 493-503. doi: 10.1517/14656566.2014.876992 PMID: 24428677
- Ibarra-Lara, L.; Sánchez-Aguilar, M.; Sánchez-Mendoza, A.; Del Valle-Mondragón, L.; Soria-Castro, E.; Carreón- Torres, E.; Díaz-Díaz, E.; Vázquez-Meza, H.; Guarner-Lans, V.; Rubio-Ruiz, M. Fenofibrate therapy restores antioxidant protection and improves myocardial insulin resistance in a rat model of metabolic syndrome and myocardial ischemia: The role of angiotensin II. Molecules, 2016, 22(1), 31. doi: 10.3390/molecules22010031 PMID: 28036029
- Tziomalos, K.; Athyros, V.; Karagiannis, A.; Mikhailidis, D. Anti-inflammatory effects of fibrates: An overview. Curr. Med. Chem., 2009, 16(6), 676-684. doi: 10.2174/092986709787458416 PMID: 19199931
- Ferretti, G.; Bacchetti, T.; Sahebkar, A. Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Prog. Lipid Res., 2015, 60, 50-73. doi: 10.1016/j.plipres.2015.08.003 PMID: 26416579
- Parizadeh, S.M.R.; Azarpazhooh, M.R.; Moohebati, M.; Nematy, M.; Ghayour-Mobarhan, M.; Tavallaie, S.; Rahsepar, A.A.; Amini, M.; Sahebkar, A.; Mohammadi, M.; Ferns, G.A.A. Simvastatin therapy reduces prooxidant-antioxidant balance: Results of a placebo-controlled cross-over trial. Lipids, 2011, 46(4), 333-340. doi: 10.1007/s11745-010-3517-x PMID: 21207250
- Sahebkar, A.; Kotani, K.; Serban, C.; Ursoniu, S.; Mikhailidis, D.P.; Jones, S.R.; Ray, K.K.; Blaha, M.J.; Rysz, J.; Toth, P.P.; Muntner, P.; Lip, G.Y.H.; Banach, M. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis, 2015, 241(2), 433-442. doi: 10.1016/j.atherosclerosis.2015.05.022 PMID: 26074317
- Sahebkar, A.; Serban, C.; Mikhailidis, D.P.; Undas, A.; Lip, G.Y.H.; Muntner, P.; Bittner, V.; Ray, K.K.; Watts, G.F.; Hovingh, G.K.; Rysz, J.; Kastelein, J.J.; Banach, M. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb. Haemost., 2015, 114(3), 546-557. PMID: 26017749
- Page, M.J.; Moher, D.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; McKenzie, J.E. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ, 2021, 372, n160. doi: 10.1136/bmj.n160 PMID: 33781993
- Wan, X.; Wang, W.; Liu, J.; Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol., 2014, 14(1), 135. doi: 10.1186/1471-2288-14-135 PMID: 25524443
- Bissonnette, R.; Treacy, E.; Rozen, R.; Boucher, B.; Cohn, J.S.; Genest, J., Jr Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis, 2001, 155(2), 455-462. doi: 10.1016/S0021-9150(00)00584-0 PMID: 11254917
- Chan, N.; Chan, J.C.N. Implication of fibrate therapy for homocysteine. Lancet, 1999, 354(9185), 1208-1209. doi: 10.1016/S0140-6736(05)75416-7 PMID: 10513737
- Cicero, A.F.G.; Derosa, G.; Miconi, A.; Laghi, L.; Nascetti, S.; Gaddi, A. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. Biomed. Pharmacother., 2005, 59(6), 312-317. doi: 10.1016/j.biopha.2004.09.014 PMID: 15932792
- Jakob, T.; Nordmann, A.J.; Schandelmaier, S.; Ferreira- González, I.; Briel, M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Libr., 2016, 2017(3), CD009753. doi: 10.1002/14651858.CD009753.pub2 PMID: 27849333
- Koutouzis, M.; Nomikos, A.; Nikolidakis, S.; Tzavara, V.; Andrikopoulos, V.; Nikolaou, N.; Barbatis, C.; Kyriakides, Z.S. Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens. Atherosclerosis, 2007, 192(2), 457-463. doi: 10.1016/j.atherosclerosis.2007.01.035 PMID: 17335827
- Lever, M.; George, P.M.; Slow, S.; Elmslie, J.L.; Scott, R.S.; Richards, A.M.; Fink, J.N.; Chambers, S.T. Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovasc. Drugs Ther., 2009, 23(5), 395-401. doi: 10.1007/s10557-009-6188-1 PMID: 19653086
- Makówka, A.; Dryja, P.; Chwatko, G.; Bald, E.; Nowicki, M. Treatment of chronic hemodialysis patients with low- dose fenofibrate effectively reduces plasma lipids and affects plasma redox status. Lipids Health Dis., 2012, 11(1), 47. doi: 10.1186/1476-511X-11-47 PMID: 22564753
- Malik, J.; Melenovsky, V.; Wichterle, D.; Haas, T.; Simek, J.; Ceska, R.; Hradec, J. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc. Res., 2001, 52(2), 290-298. doi: 10.1016/S0008-6363(01)00382-0 PMID: 11684077
- Mayer, O., Jr; imon, J.; Holubec, L.; Pikner, R.; Trefil, L. Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates. Physiol. Res., 2006, 55(5), 475-481. doi: 10.33549/physiolres.930856 PMID: 16343039
- Mayer, O., Jr; imon, J.; Holubec, L.; Pikner, R.; ubrt, I. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. Eur. J. Clin. Pharmacol., 2003, 59(5-6), 367-371. doi: 10.1007/s00228-003-0616-0 PMID: 12845504
- Nanayakkara, P.W.B.; Kiefte-de Jong, J.C.; Stehouwer, C.D.A.; van Ittersum, F.J.; Olthof, M.R.; Kok, R.M.; Blom, H.J.; van Guldener, C.; ter Wee, P.M.; Smulders, Y.M. Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2-4 chronic kidney disease. Nephrol. Dial. Transplant., 2008, 23(8), 2586-2592. doi: 10.1093/ndt/gfn040 PMID: 18287179
- Nanayakkara, P.W.B.; Kiefte-de Jong, J.C.; ter Wee, P.M.; Stehouwer, C.D.A.; van Ittersum, F.J.; Olthof, M.R.; Teerlink, T.; Twisk, J.W.R.; van Guldener, C.; Smulders, Y.M. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. Am. J. Kidney Dis., 2009, 53(1), 41-50. doi: 10.1053/j.ajkd.2008.06.016 PMID: 18786751
- Sbarouni, E.; Kyriakides, Z.S.; Kremastinos, D.T. The effect of hormone replacement therapy and simvastatin on plasma homocysteine. J. Womens Health, 2005, 14(2), 154-158. doi: 10.1089/jwh.2005.14.154 PMID: 15775733
- Sinzinger, H.; Steiner, S.; Derfler, K. Pleiotropic effects of regular lipoprotein-apheresis. Atheroscler. Suppl., 2017, 30, 122-127. doi: 10.1016/j.atherosclerosissup.2017.05.032 PMID: 29096827
- Veringa, S.J.E.; Nanayakkara, P.W.B.; Ittersum, F.J.; Vegting, I.L.; Guldener, C.; Wee, Y.M.S.P.M.; Stehouwer, C.D.A.; Stehouwer, C.D. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on arterial compliance and distensibility in patients with mild-to-moderate chronic kidney disease. Clin. Nephrol., 2012, 78(10), 263-272. doi: 10.5414/CN107439 PMID: 22981031
- Wenaweser, P.; Windecker, S.; Billinger, M.; Cook, S.; Togni, M.; Meier, B.; Haeberli, A.; Hess, O.M. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. Am. J. Cardiol., 2007, 99(3), 353-356. doi: 10.1016/j.amjcard.2006.08.036 PMID: 17261397
- Hovland, A.; Aagnes, I.; Brekke, O.L.; Flage, J.H.; Lappegård, K.T. No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins. J. Clin. Lipidol., 2010, 4(4), 288-292. doi: 10.1016/j.jacl.2010.02.011 PMID: 21122661
- El Oudi, M.; Aouni, Z.; Ouertani, H.; Mazigh, C.; Machghoul, S. Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics. Vasc. Health Risk Manag., 2010, 6, 327-332. doi: 10.2147/VHRM.S8240 PMID: 20531951
- Stulc, T.; Ceska, R.; Kozich, V.; Skrha, J. 2P-0372 Fenofibrate but not simvastatin increases serum homocysteine and creatinine in patients with type 2 diabetes mellitus. Atheroscler. Suppl., 2003, 4(2), 120. doi: 10.1016/S1567-5688(03)90515-0
- Dierkes, J.; Westphal, S.; Luley, C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet, 1999, 354(9174), 219-220. doi: 10.1016/S0140-6736(99)02153-4 PMID: 10421307
- Feng, Y.; Liang, W.; Liang, W.; Xiao, X.; Zhang, Y. Effects of XueZhiTong capsules on chronic kidney disease patients with dyslipidemia. Trop. J. Pharm. Res., 2022, 21(1), 177-183.
- Potaczek, D.P.; Undas, A.; Celinska-Lowenhoff, M.; Szczeklik, A. The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects. Cardiovasc. Drugs Ther., 2006, 20(3), 229-232. doi: 10.1007/s10557-006-8374-8 PMID: 16779534
- Pytel, E.; Jackowska, P.; Chwatko, G.; Olszewska-Banaszczyk, M.; Koter-Michalak, M.; Kubalczyk, P.; Broncel, M. Intensive statin therapy, used alone or in combination with ezetimibe, improves homocysteine level and lipid peroxidation to a similar degree in patients with coronary artery diseases. Pharmacol. Rep., 2016, 68(2), 344-348. doi: 10.1016/j.pharep.2015.08.019 PMID: 26922537
- Vladimirova-Kitova, L.G.; Deneva-Koycheva, T.I. The effect of simvastatin on asymmetric dimethylarginine and flow-mediated vasodilation after optimizing the LDL level - A randomized, placebo-controlled study. Vascul. Pharmacol., 2012, 56(3-4), 122-130. doi: 10.1016/j.vph.2011.10.004 PMID: 22108444
- Zhou, T.; Mei, J.; Hou, M. Clinical study of double anti- platelet therapy combined with different doses of statin in the treatment of acute cerebral infarction complicated with microhemorrhage. Am. J. Transl. Res., 2021, 13(10), 12043-12050. PMID: 34786140
- Peng, Y.; Ou, B.Q.; Li, H.H.; Zhou, Z.; Mo, J.L.; Huang, J.; Liang, F.L. Synergistic effect of atorvastatin and folic acid on cardiac function and ventricular remodeling in chronic heart failure patients with hyperhomocysteinemia. Med. Sci. Monit., 2018, 24, 3744-3751. doi: 10.12659/MSM.906893 PMID: 29863106
- Genest, J.; Frohlich, J.; Steiner, G. Effect of fenofibrate- mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am. J. Cardiol., 2004, 93(7), 848-853. doi: 10.1016/j.amjcard.2003.12.022 PMID: 15050487
- Krysiak, R.; Kowalcze, K.; Bednarska-Czerwińska, A.; Okopień, B. The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study. Pharmacol. Rep., 2019, 71(3), 417-421. doi: 10.1016/j.pharep.2019.01.014 PMID: 31003151
- Mok, C.C.; Wong, C.K.; To, C.H.; Lai, J.P.S.; Lam, C.S. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double-blind, placebo-controlled trial. Arthritis Care Res., 2011, 63(6), 875-883. doi: 10.1002/acr.20440 PMID: 21309005
- Pinchbeck, J.L.; Moxon, J.V.; Rowbotham, S.E.; Bourke, M.; Lazzaroni, S.; Morton, S.K.; Matthews, E.O.; Hendy, K.; Jones, R.E.; Bourke, B.; Jaeggi, R.; Favot, D.; Quigley, F.; Jenkins, J.S.; Reid, C.M.; Velu, R.; Golledge, J. Randomized placebo-controlled trial assessing the effect of 24-week fenofibrate therapy on circulating markers of abdominal aortic aneurysm: Outcomes from the FAME-2 trial. J. Am. Heart Assoc., 2018, 7(19), e009866. doi: 10.1161/JAHA.118.009866 PMID: 30371299
- van der Loo, B.; Spring, S.; Koppensteiner, R. High-dose atorvastatin treatment in patients with peripheral arterial disease: Effects on platelet aggregation, blood rheology and plasma homocysteine. Clin. Hemorheol. Microcirc., 2011, 47(4), 241-251. doi: 10.3233/CH-2011-1386 PMID: 21654053
- Janatuinen, T.; Laakso, J.; Laaksonen, R.; Vesalainen, R.; Nuutila, P.; Lehtimäki, T.; Raitakari, O.T.; Knuuti, J. Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vasc. Med., 2003, 8(3), 185-189. doi: 10.1191/1358863x03vm490oa PMID: 14989559
- Li, C.; Ding, Y.; Si, Q.; Li, K.; Xu, K. Multiple functions of policosanol in elderly patients with dyslipidemia. J. Int. Med. Res., 2020, 48(7), 0300060520936082. doi: 10.1177/0300060520936082 PMID: 32703038
- MacCallum, P.K.; Cooper, J.A.; Rumley, A.; Lowe, G.D.O.; Meade, T.W. Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease. J. Thromb. Haemost., 2004, 2(2), 346-379. doi: 10.1111/j.1538-7933.2004.0584l.x PMID: 14996019
- Milionis, H.J.; Papakostas, J.; Kakafika, A.; Chasiotis, G.; Seferiadis, K.; Elisaf, M.S. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J. Clin. Pharmacol., 2003, 43(8), 825-830. doi: 10.1177/0091270003255920 PMID: 12953339
- Nanayakkara, P.W.B.; van Guldener, C.; ter Wee, P.M.; Scheffer, P.G.; van Ittersum, F.J.; Twisk, J.W.; Teerlink, T.; van Dorp, W.; Stehouwer, C.D. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: Results from the Anti-Oxidant therapy in chronic renal insufficiency (ATIC) Study. Arch. Intern. Med., 2007, 167(12), 1262-1270. doi: 10.1001/archinte.167.12.1262 PMID: 17592099
- Nieminen, T.; Knuuti, J.; Hämelahti, P.; Kähönen, M.; Laaksonen, R.; Janatuinen, T.; Vesalainen, R.; Nuutila, P.; Jokela, H.; Lehtimäki, T. Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy. Vascul. Pharmacol., 2007, 47(2-3), 113-117. doi: 10.1016/j.vph.2007.05.001 PMID: 17574929
- Ridker, P.M.; Shih, J.; Cook, T.J.; Clearfield, M.; Downs, J.R.; Pradhan, A.D.; Weis, S.E.; Gotto, A.M., Jr Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation, 2002, 105(15), 1776-1779. doi: 10.1161/01.CIR.0000014447.06099.FB PMID: 11956118
- Li, C.; Bu, X.; Liu, Y. Effect of folic acid combined with pravastatin on arteriosclerosis in elderly hypertensive patients with lacunar infarction. Medicine, 2021, 100(28), e26540. doi: 10.1097/MD.0000000000026540 PMID: 34260532
- Deng, Y.; Zou, W.; Chen, G.; Shangguan, S.; Zhou, F.; Jiang, W.; Li, X. Comparative studies on the effects of different doses of atorvastatin combined with aspirin on inflammatory cytokines and carotid plaques in patients with ischemic cerebrovascular disease. Int. J. Neurosci., 2019, 129(11), 1133-1138. doi: 10.1080/00207454.2019.1635592 PMID: 31232139
- Tan, Q.; Zhang, S.; Zou, X.; Zhao, J.; Hao, J.; Sun, Q. Fluvastatin therapy could not decrease progression of paroxysmal atrial fibrillation in non-valvular disease patients. Anatol. J. Cardiol., 2017, 18(2), 103-107. doi: 10.14744/AnatolJCardiol.2017.7664 PMID: 28430117
- Sebestjen, M.; Keber, I.; Zegura, B.; Simcic, S.; Bozic, M.; Fressart, M.M.; Stegnar, M. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb. Haemost., 2004, 92(5), 1129-1135. PMID: 15543343
- Playford, D.A.; Watts, G.F.; Croft, K.D.; Burke, V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis, 2003, 168(1), 169-179. doi: 10.1016/S0021-9150(02)00417-3 PMID: 12732401
- Niafar, M; Bahrami, A; Lotfi Yagin, N; Najafipour, F; Aghamohammadzadeh, N; Sadra, V. Effect of high dose versus low dose of atorvastatin therapy on inflammation and coagulation factors in type 2 diabetic patients; a randomized clinical trial study. Immunopathol Persa, 2019, 5(1), e01-e. doi: 10.15171/ipp.2019.01
- Krysiak, R.; Gilowski, W.; Okopien, B. The effect of testosterone and fenofibrate, administered alone or in combination, on cardiometabolic risk factors in men with late-onset hypogonadism and atherogenic dyslipidemia. Cardiovasc. Ther., 2015, 33(5), 270-274. doi: 10.1111/1755-5922.12139 PMID: 26031507
- Westphal, S.; Dierkes, J.; Luley, C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet, 2001, 358(9275), 39-40. doi: 10.1016/S0140-6736(00)05271-5 PMID: 11454380
- Carrero, J.J.; López-Huertas, E.; Salmerón, L.M.; Ramos, V.E.; Baró, L.; Ros, E. Simvastatin and supplementation with ω-3 polyunsaturated fatty acids and vitamins improves claudication distance in a randomized PILOT study in patients with peripheral vascular disease. Nutr. Res., 2006, 26(12), 637-643. doi: 10.1016/j.nutres.2006.09.024
- Giral, P.; Bruckert, E.; Jacob, N.; Chapman, M.J.; Foglietti, M.J.; Turpin, G. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis, 2001, 154(2), 421-427. doi: 10.1016/S0021-9150(00)00474-3 PMID: 11166775
- Harats, D.; Yodfat, O.; Doolman, R.; Gavendo, S.; Marko, D.; Shaish, A.; Sela, B.A. Homocysteine elevation with fibrates: Is it a class effect? Isr. Med. Assoc. J., 2001, 3(4), 243-246. PMID: 11344833
- Herrmann, M.; Whiting, M.J.; Veillard, A.S.; Ehnholm, C.; Sullivan, D.R.; Keech, A.C. Plasma homocysteine and the risk of venous thromboembolism: Insights from the FIELD study. Clin. Chem. Lab. (CCLM), 2012, 50(12), 2213-2219. doi: 10.1515/cclm-2012-0078 PMID: 23093273
- Kaya, C.; Cengiz, S.D.; Berker, B.; Demirtaş, S.; Cesur, M.; Erdoğan, G. Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: A prospective randomized study. Fertil. Steril., 2009, 92(2), 635-642. doi: 10.1016/j.fertnstert.2008.06.006 PMID: 18692805
- Lu, T.M.; Ding, Y.A.; Leu, H.B.; Yin, W.H.; Sheu, W.H.H.; Chu, K.M. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am. J. Cardiol., 2004, 94(2), 157-161. doi: 10.1016/j.amjcard.2004.03.052 PMID: 15246890
- Melenovsky, V.; Malik, J.; Wichterle, D.; Simek, J.; Pisarikova, A.; Skrha, J.; Poledne, R.; Stavek, P.; Ceska, R. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am. Heart J., 2002, 144(4), E6. doi: 10.1016/S0002-8703(02)00142-4 PMID: 12360175
- Santini, E.; Madec, S.; Corretti, V.; Ferrannini, E.; Solini, A. Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients. J. Endocrinol. Invest., 2008, 31(7), 660-665. doi: 10.1007/BF03345621 PMID: 18787388
- Syvänne, M.; Whittall, R.A.; Turpeinen, U.; Nieminen, M.S.; Frick, M.H.; Kesäniemi, Y.A.; Pasternack, A.; Humphries, S.E.; Taskinen, M.R. Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis, 2004, 172(2), 267-272. doi: 10.1016/j.atherosclerosis.2003.10.003 PMID: 15019536
- Vigna, G.B.; Donegà, P.; Zanca, R.; Barban, A.; Passaro, A.; Pansini, F.; Bonaccorsi, G.; Mollica, G.; Fellin, R. Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: A randomized, placebo-controlled clinical trial. Metabolism, 2002, 51(11), 1463-1470. doi: 10.1053/meta.2002.35584 PMID: 12404199
- Vladimirova-Kitova, L.G.; Deneva, T.I.; Marinov, B. Effect of moderate and high-dose simvastatin on asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia. Cardiovasc. Ther., 2011, 29(5), 340-348. doi: 10.1111/j.1755-5922.2010.00149.x PMID: 20345493
- Haak, E.; Abletshauser, C.; Weber, S.; Goedicke, C.; Martin, N.; Hermanns, N.; Lackner, K.; Kusterer, K.; Usadel, K.H.; Haak, T. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis, 2001, 155(2), 395-401. doi: 10.1016/S0021-9150(00)00567-0 PMID: 11254910
- Derosa, G.; Maffioli, P.; Salvadeo, S.A.T.; Ferrari, I.; Gravina, A.; Mereu, R.; Palumbo, I.; Dangelo, A.; Cicero, A.F.G. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr. Med. Res. Opin., 2009, 25(8), 1973-1983. doi: 10.1185/03007990903073159 PMID: 19555253
- Davidson, M.H.; Rooney, M.W.; Drucker, J.; Eugene Griffin, H.; Oosman, S.; Beckert, M. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double-blind, randomized, parallel-group study. Clin. Ther., 2009, 31(12), 2824-2838. doi: 10.1016/j.clinthera.2009.12.007 PMID: 20110022
- Feng, T.; Huang, X.; Liang, Q.; Liang, Y.; Yuan, Y.; Feng, L.; Wu, W.; Xiao, X.; Han, Y. effects of pitavastatin on lipid-rich carotid plaques studied using high-resolution magnetic resonance imaging. Clin. Ther., 2017, 39(3), 620-629. doi: 10.1016/j.clinthera.2017.01.013 PMID: 28185713
- Ishibashi, S.; Arai, H.; Yokote, K.; Araki, E.; Suganami, H.; Yamashita, S. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J. Clin. Lipidol., 2018, 12(1), 173-184. doi: 10.1016/j.jacl.2017.10.006 PMID: 29203092
- Kim, D.W.; Kim, H.K.; Bae, E.K. The effects of lifestyle modification and statin therapy on the circulatory markers for vascular risk in patients with epilepsy. Epilepsy Behav., 2017, 76, 133-135. doi: 10.1016/j.yebeh.2017.08.041 PMID: 28927716
- Lee, S.H.; Cho, K.I.; Kim, J.Y.; Ahn, Y.K.; Rha, S.W.; Kim, Y.J.; Choi, Y.S.; Choi, S.W.; Jeon, D.W.; Min, P.K.; Choi, D.J.; Baek, S.H.; Kim, K.S.; Byun, Y.S.; Jang, Y. Non-lipid effects of rosuvastatinfenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia. Atherosclerosis, 2012, 221(1), 169-175. doi: 10.1016/j.atherosclerosis.2011.12.042 PMID: 22269152
- Wang, G.; He, L.; Liu, J.; Yu, J.; Feng, X.; Li, F.; Hao, Y.; Mao, J.; Hong, T.; Chen, A.F.; Wang, X. Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia. Cardiovasc. Ther., 2013, 31(3), 161-167. doi: 10.1111/j.1755-5922.2011.00307.x PMID: 22280018
- Wang, H.; Zhang, Z.; Sun, J. The clinical evaluation of combined detection of microcirculation, lipid metabolism, and inflammatory-related factors in the treatment of diabetic nephropathy with atorvastatin. Eur. J. Inflamm., 2019, 17, 2058739219847830.
- Chen, W.; Tian, T.; Wang, S.; Xue, Y.; Sun, Z.; Wang, S. Characteristics of carotid atherosclerosis in elderly patients with type 2 diabetes at different disease course, and the intervention by statins in very elderly patients. J. Diabetes Investig., 2018, 9(2), 389-395. doi: 10.1111/jdi.12710 PMID: 28685957
- de Lorgeril, M.; Salen, P.; Paillard, F.; Lacan, P.; Richard, G. Lipid-lowering drugs and homocysteine. Lancet, 1999, 353(9148), 209-210. doi: 10.1016/S0140-6736(05)77220-2 PMID: 9923885
- Ansquer, J.C.; Dalton, R.N.; Caussé, E.; Crimet, D.; Le Malicot, K.; Foucher, C. Effect of fenofibrate on kidney function: A 6-week randomized crossover trial in healthy people. Am. J. Kidney Dis., 2008, 51(6), 904-913. doi: 10.1053/j.ajkd.2008.01.014 PMID: 18501783
- Wustmann, K.; Klaey, M.; Burow, A.; Shaw, S.G.; Hess, O.M.; Allemann, Y. Additive effect of homocysteine- and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular disease. Cardiovasc. Ther., 2012, 30(5), 277-286. doi: 10.1111/j.1755-5922.2011.00272.x PMID: 21884007
- Chong, P.H.; Seeger, J.D.; Franklin, C. Clinically relevant differences between the statins: Implications for therapeutic selection. Am. J. Med., 2001, 111(5), 390-400. doi: 10.1016/S0002-9343(01)00870-1 PMID: 11583643
- Poddar, R.; Sivasubramanian, N.; DiBello, P.M.; Robinson, K.; Jacobsen, D.W. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: Implications for vascular disease. Circulation, 2001, 103(22), 2717-2723. doi: 10.1161/01.CIR.103.22.2717 PMID: 11390343
- Zeng, X.; Guan, Y.; Remick, D.G.; Wang, X. Signal pathways underlying homocysteine-induced production of MCP-1 and IL-8 in cultured human whole blood. Acta Pharmacol. Sin., 2005, 26(1), 85-91. doi: 10.1111/j.1745-7254.2005.00005.x PMID: 15659119
- Cai, T.; Abel, L.; Langford, O.; Monaghan, G.; Aronson, J.K.; Stevens, R.J.; Lay-Flurrie, S.; Koshiaris, C.; McManus, R.J.; Hobbs, F.D.R.; Sheppard, J.P. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ, 2021, 374(1537), n1537. doi: 10.1136/bmj.n1537 PMID: 34261627
- Koushki, K.; Shahbaz, S.K.; Mashayekhi, K.; Sadeghi, M.; Zayeri, Z.D.; Taba, M.Y.; Banach, M.; Al-Rasadi, K.; Johnston, T.P.; Sahebkar, A. Anti-inflammatory action of statins in cardiovascular disease: The role of inflammasome and toll-like receptor pathways. Clin. Rev. Allergy Immunol., 2021, 60(2), 175-199. doi: 10.1007/s12016-020-08791-9 PMID: 32378144
- Bahrami, A.; Parsamanesh, N.; Atkin, S.L.; Banach, M.; Sahebkar, A. Effect of statins on toll-like receptors: A new insight to pleiotropic effects. Pharmacol. Res., 2018, 135, 230-238. doi: 10.1016/j.phrs.2018.08.014 PMID: 30120976
- Khalifeh, M.; Penson, P.; Banach, M.; Sahebkar, A. Statins as anti-pyroptotic agents. Arch. Med. Sci., 2021, 17(5), 1414-1417. doi: 10.5114/aoms/141155 PMID: 34522271
- Shakour, N.; Ruscica, M.; Hadizadeh, F.; Cirtori, C.; Banach, M.; Jamialahmadi, T.; Sahebkar, A. Statins and C-reactive protein: In silico evidence on direct interaction. Arch. Med. Sci., 2020, 16(6), 1432-1439. doi: 10.5114/aoms.2020.100304 PMID: 33224343
- Morita, H.; Saito, Y.; Ohashi, N.; Yoshikawa, M.; Katoh, M.; Ashida, T.; Kurihara, H.; Nakamura, T.; Kurabayashi, M.; Nagai, R. Fluvastatin ameliorates the hyperhomocysteinemia-induced endothelial dysfunction: The antioxidative properties of fluvastatin. Circ. J., 2005, 69(4), 475-480. doi: 10.1253/circj.69.475 PMID: 15791046
- Sahebkar, A.; Pećin, I.; Tedeschi-Reiner, E.; Derosa, G.; Maffioli, P.; Reiner, . Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. Int. J. Cardiol., 2016, 212, 160-168. doi: 10.1016/j.ijcard.2016.03.010 PMID: 27038725
- Redfearn, D.P.; Trim, G.M.; Skanes, A.C.; Petrellis, B.; Krahn, A.D.; Yee, R.; Klein, G.J. Esophageal temperature monitoring during radiofrequency ablation of atrial fibrillation. J. Cardiovasc. Electrophysiol., 2005, 16(6), 589-593. doi: 10.1111/j.1540-8167.2005.40825.x PMID: 15946354
- Schroecksnadel, K.; Frick, B.; Winkler, C.; Wirleitner, B.; Weiss, G.; Fuchs, D. Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells. Clin. Chem. Lab. Med., 2005, 43(12), 1373-1376. doi: 10.1515/CCLM.2005.234 PMID: 16309375
- Amioka, N.; Miyoshi, T. Fibrates: A possible treatment option for patients with abdominal aortic aneurysm? Biomolecules, 2022, 12(1), 74. doi: 10.3390/biom12010074 PMID: 35053222
- Inoue, I.; Goto, S.; Matsunaga, T.; Nakajima, T.; Awata, T.; Hokari, S.; Komoda, T.; Katayama, S. The ligands/activators for peroxisome proliferator-activated receptor α (PPARα) and PPARγ increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism, 2001, 50(1), 3-11. doi: 10.1053/meta.2001.19415 PMID: 11172467
- Zinellu, A.; Mangoni, A.A. A systematic review and meta- analysis of the effect of statins on glutathione peroxidase, superoxide dismutase, and catalase. Antioxidants, 2021, 10(11), 1841. doi: 10.3390/antiox10111841 PMID: 34829712
- Morillas-Ruiz, J.M.; Rubio-Perez, J.M.; Albaladejo, M.D.; Zafrilla, P.; Parra, S.; Vidal-Guevara, M.L. Effect of an antioxidant drink on homocysteine levels in Alzheimers patients. J. Neurol. Sci., 2010, 299(1-2), 175-178. doi: 10.1016/j.jns.2010.08.050 PMID: 20850133
- Peng, X.; Gao, Q.; Zhou, J.; Ma, J.; Zhao, D.; Hao, L. Association between dietary antioxidant vitamins intake and homocysteine levels in middle-aged and older adults with hypertension: A cross-sectional study. BMJ Open, 2021, 11(10), e045732. doi: 10.1136/bmjopen-2020-045732 PMID: 34642187
- Gouédard, C.; Koum-Besson, N.; Barouki, R.; Morel, Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol. Pharmacol., 2003, 63(4), 945-956. doi: 10.1124/mol.63.4.945 PMID: 12644596
- Foucher, C.; Brugère, L.; Ansquer, J.C. Fenofibrate, homocysteine and renal function. Curr. Vasc. Pharmacol., 2010, 8(5), 589-603. doi: 10.2174/157016110792006987 PMID: 20507276
- Hadjivasilis, A.; Kouis, P.; Kousios, A.; Panayiotou, A. The effect of fibrates on kidney function and chronic kidney disease progression: A systematic review and meta-analysis of randomised studies. J. Clin. Med., 2022, 11(3), 768. doi: 10.3390/jcm11030768 PMID: 35160220
- Goffin, E.; Jamar, F.; Desager, J.P.; Devuyst, O. Implication of fibrate therapy for homocysteine.. Lancet, 1999, 354(9185), 1209. doi: 10.1016/S0140-6736(05)75417-9 PMID: 10513738
- Zhang, Z.; Gu, X.; Fang, X.; Tang, Z.; Guan, S.; Liu, H.; Wu, X.; Wang, C.; Zhao, Y. Homocysteine and the risk of cardiovascular events and all-cause death in elderly population: A community-based prospective cohort study. Ther. Clin. Risk Manag., 2020, 16, 471-481. doi: 10.2147/TCRM.S239496 PMID: 32547044
- Huo, Y.; Li, J.; Qin, X.; Huang, Y.; Wang, X.; Gottesman, R.F.; Tang, G.; Wang, B.; Chen, D.; He, M.; Fu, J.; Cai, Y.; Shi, X.; Zhang, Y.; Cui, Y.; Sun, N.; Li, X.; Cheng, X.; Wang, J.; Yang, X.; Yang, T.; Xiao, C.; Zhao, G.; Dong, Q.; Zhu, D.; Wang, X.; Ge, J.; Zhao, L.; Hu, D.; Liu, L.; Hou, F.F. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: The CSPPT randomized clinical trial. JAMA, 2015, 313(13), 1325-1335. doi: 10.1001/jama.2015.2274 PMID: 25771069
- Blais, J.E.; Tong, G.K.Y.; Pathadka, S.; Mok, M.; Wong, I.C.K.; Chan, E.W. Comparative efficacy and safety of statin and fibrate monotherapy: A systematic review and meta-analysis of head-to-head randomized controlled trials. PLoS One, 2021, 16(2), e0246480. doi: 10.1371/journal.pone.0246480 PMID: 33561179
- Terra, S.G.; Francone, O.L.; Contant, C.F.; Gao, X.; Lewin, A.J.; Nguyen, T.T. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus. Am. J. Cardiol., 2008, 102(4), 434-439.
Supplementary files
